Promega licenses Broad Institute’s CRISPR-Cas9 intellectual property

Promega has licensed the Broad Institute’s CRISPR-Cas9 intellectual property on a non-exclusive basis. The terms of the agreement state that Promega will combine the Broad’s CRISPR-Cas9 technology with its own products for knock-in of genetic reporters into the genomes of any cell or cell line. The company wants to develop and sell gene editing tools and reagents for interrogating endogenous biology at physiologically relevant expression levels. A paper published in ACS Chemical Biology in 2017 showed that the Promega HiBiT Protein Tagging System can be combined with CRISPR-Cas9-mediated gene editing to tag endogenous proteins and simplify their study under natural expression conditions.
Senior Research Scientist at Promega, Thomas Machleidt, said: “With this combination of CRISPR and our most advanced reporter technologies like HiBiT, we are able to look at the dynamics of endogenous proteins in real time with unprecedented ease and sensitivity.”